[Systematic neonatal screening for Duchenne muscular dystrophy].
More than 15% of cases of Duchenne muscular dystrophy (DMD) may be preventable by the neonatal diagnosis of another affected relative. Systematic neonatal screening seems a more efficient way of getting information for genetic counseling. The principle of the test described is the detection of a specific increase of the activity of Creatine-Kinase (CK) in the blood of newborn children with myopathy. Blood may be spotted on paper and posted to a central laboratory. Furthermore this program can be integrated into the systematic screening of phenylketonurie. The specificity and accuracy of the bioluminescent reaction used for the evaluation of CK suggest that this screening reaction is reliable. A systematic neonatal screening program for DMD such as ours in the Rhône-Alpes area (France) will lead to frequent recourse to prenatal diagnosis now possible through sex fetal determination and which would be possible through in utero blood sampling.
D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005817:Genetic Counseling; D005820:Genetic Testing; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009136:Muscular Dystrophies / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control*; D011247:Pregnancy; D011296:Prenatal Diagnosis; D012737:Sex Factors
D003402:Creatine Kinase
Dépistage néonatal systématique de la myopathie de Duchenne de Boulogne (author's transl)]